29 related articles for article (PubMed ID: 21428246)
1. Medication practice in hospitals: are nanosimilars evaluated and substituted correctly?
Knoeff J; Flühmann B; Mühlebach S
Eur J Hosp Pharm; 2018 Mar; 25(2):79-84. PubMed ID: 29599970
[TBL] [Abstract][Full Text] [Related]
2. Comparative Evaluation of U.S. Brand and Generic Intravenous Sodium Ferric Gluconate Complex in Sucrose Injection: Physicochemical Characterization.
Sun D; Rouse R; Patel V; Wu Y; Zheng J; Karmakar A; Patri AK; Chitranshi P; Keire D; Ma J; Jiang W
Nanomaterials (Basel); 2018 Jan; 8(1):. PubMed ID: 29303999
[TBL] [Abstract][Full Text] [Related]
3. Comparison of oxidative stress and inflammation induced by different intravenous iron sucrose similar preparations in a rat model.
Toblli JE; Cao G; Oliveri L; Angerosa M
Inflamm Allergy Drug Targets; 2012 Feb; 11(1):66-78. PubMed ID: 22309085
[TBL] [Abstract][Full Text] [Related]
4. Physicochemical Characterization of Iron Carbohydrate Colloid Drug Products.
Zou P; Tyner K; Raw A; Lee S
AAPS J; 2017 Sep; 19(5):1359-1376. PubMed ID: 28762128
[TBL] [Abstract][Full Text] [Related]
5. Biodistribution and predictive hepatic gene expression of intravenous iron sucrose.
Elford P; Bouchard J; Jaillet L; Pearson N; Rogue A; Sabadie C; Forster R
J Pharmacol Toxicol Methods; 2013; 68(3):374-83. PubMed ID: 23624021
[TBL] [Abstract][Full Text] [Related]
6. Differences between original intravenous iron sucrose and iron sucrose similar preparations.
Toblli JE; Cao G; Oliveri L; Angerosa M
Arzneimittelforschung; 2009; 59(4):176-90. PubMed ID: 19517894
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the extent of oxidative stress induced by intravenous ferumoxytol, ferric carboxymaltose, iron sucrose and iron dextran in a nonclinical model.
Toblli JE; Cao G; Oliveri L; Angerosa M
Arzneimittelforschung; 2011; 61(7):399-410. PubMed ID: 21899208
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of toxicity and oxidative stress induced by intravenous iron isomaltoside 1000 in a nonclinical model.
Toblli JE; Cao G; Oliveri L; Angerosa M
Arzneimittelforschung; 2011; 61(10):553-65. PubMed ID: 22164963
[TBL] [Abstract][Full Text] [Related]
9. Physicochemical and structural characterization of iron-sucrose formulations: a comparative study.
Barot BS; Parejiya PB; Mehta DM; Shelat PK; Shah GB
Pharm Dev Technol; 2014 Aug; 19(5):513-20. PubMed ID: 23701359
[TBL] [Abstract][Full Text] [Related]
10. Physicochemical and toxicological characterization of a new generic iron sucrose preparation.
Meier T; Schropp P; Pater C; Leoni AL; Khov-Tran VV; Elford P
Arzneimittelforschung; 2011; 61(2):112-9. PubMed ID: 21428246
[TBL] [Abstract][Full Text] [Related]
11. The new generation of intravenous iron: chemistry, pharmacology, and toxicology of ferric carboxymaltose.
Funk F; Ryle P; Canclini C; Neiser S; Geisser P
Arzneimittelforschung; 2010; 60(6a):345-53. PubMed ID: 20648926
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]